Intercure(US:INCR) Globenewswireยท2025-10-08 13:02Core Insights - InterCure Ltd. reported NIS 130 million in revenue for the first half of 2025, marking a 15% increase compared to the second half of 2024 and a 3% increase compared to the first half of 2024, alongside positive operating cash flow of NIS 12 million [5][2][1] - The company achieved positive Adjusted EBITDA for the eleventh consecutive half, demonstrating resilience amid challenging conditions, including the impact of the October 7 attack and the ongoing war in Gaza [2][3] - InterCure is strategically positioned to capitalize on evolving U.S. cannabis regulations, particularly following its agreement to acquire ISHI, which is expected to enhance its market presence and product offerings [1][3][5] Financial Highlights - Revenue for the first half of 2025 was NIS 130 million, with a net loss of NIS 1.8 million compared to near break-even in the first half of 2024 [5][14] - Adjusted EBITDA was NIS 12.6 million, representing 10% of revenue, and positive cash flow from operations was NIS 12 million, a significant improvement from negative cash flow of NIS 43 million in the same period last year [5][14] - Cash on hand increased to NIS 54 million as of June 30, 2025, compared to NIS 21 million a year earlier, indicating improved liquidity [5][12] Operational and Strategic Developments - The company resumed production, importation, and sales from its Nir Oz facility, delivering the first batches since the October 7 attack [5][2] - InterCure launched over 40 new SKUs during the first half of 2025, marking its first major product launches since October 2023 [5] - The company received NIS 81 million in compensation advances from Israeli authorities for war-related damages, part of a total claim of NIS 251 million [5][19] - The acquisition of ISHI is expected to strengthen InterCure's access to premium U.S. genetics and advanced cultivation technologies, contributing tens of millions of shekels to revenues [5][6]